Junxiu Yu1,2, Wanlei Zheng3,4. 1. Department of Gastrointestinal Surgery, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, People's Republic of China. yujxcn@hotmail.com. 2. Department of Gastrointestinal Surgery, Liaocheng People's Hospital, 67 Dongchang West Road, Dongchangfu District, Liaocheng, Shandong Province, 252000, People's Republic of China. yujxcn@hotmail.com. 3. Department of Gastrointestinal Surgery, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, People's Republic of China. 4. Department of Gastrointestinal Surgery, Liaocheng People's Hospital, 67 Dongchang West Road, Dongchangfu District, Liaocheng, Shandong Province, 252000, People's Republic of China.
Abstract
PURPOSE: The goal of this study was to create a novel method for screening gastric cancer (GC) based on serum levels of carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4) tumor markers. METHODS: Retrospectively, the predictive value for GC was calculated using a logistic analysis on serum levels of CEA, CA19-9, and CA72-4 from 216 GC and 49 benign patients. The predictive value was used to make a recommendation system on whether further GC screening was necessary. Prospectively, 80 GC and 33 benign patients were used to assess the value of this method. RESULTS: The recommendation system to determine whether additional GC screening was necessary consisted of three grades: grade I, no proposals; grade II, proposals; grade III, strong proposals. Additional screening was suggested when the predictive value was ≤0.700 (grade I), 0.700-0.850 (grade II), and >0.850 (grade III). Of the total 216 GC patients, 20.4, 27.8, and 51.9% were classified as grades I, II, and III, respectively. Of the 49 benign cases, 57.1, 32.7, and 10.2% were classified as grades I, II, and III, respectively. Of the 80 prospective GC patients, 17.3, 28.4, and 54.3% were classified as grades I, II, and III, respectively. Of the 33 prospective benign cases, 54.6, 33.3, and 12.1% were classified as grades I, II, and III, respectively. CONCLUSION: The new screening recommendation system based on serum levels of CEA, CA19-9, and CA72-4 is an effective approach for detecting GC.
PURPOSE: The goal of this study was to create a novel method for screening gastric cancer (GC) based on serum levels of carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4) tumor markers. METHODS: Retrospectively, the predictive value for GC was calculated using a logistic analysis on serum levels of CEA, CA19-9, and CA72-4 from 216 GC and 49 benignpatients. The predictive value was used to make a recommendation system on whether further GC screening was necessary. Prospectively, 80 GC and 33 benign patients were used to assess the value of this method. RESULTS: The recommendation system to determine whether additional GC screening was necessary consisted of three grades: grade I, no proposals; grade II, proposals; grade III, strong proposals. Additional screening was suggested when the predictive value was ≤0.700 (grade I), 0.700-0.850 (grade II), and >0.850 (grade III). Of the total 216 GC patients, 20.4, 27.8, and 51.9% were classified as grades I, II, and III, respectively. Of the 49 benign cases, 57.1, 32.7, and 10.2% were classified as grades I, II, and III, respectively. Of the 80 prospective GC patients, 17.3, 28.4, and 54.3% were classified as grades I, II, and III, respectively. Of the 33 prospective benign cases, 54.6, 33.3, and 12.1% were classified as grades I, II, and III, respectively. CONCLUSION: The new screening recommendation system based on serum levels of CEA, CA19-9, and CA72-4 is an effective approach for detecting GC.
Entities:
Keywords:
CA19-9; CA72-4; CEA; Mass screening; Stomach neoplasms; Tumor markers
Authors: D Marrelli; C Pedrazzani; P Morgagni; G de Manzoni; F Pacelli; A Coniglio; A Marchet; L Saragoni; S Giacopuzzi; F Roviello Journal: Br J Surg Date: 2011-05-10 Impact factor: 6.939
Authors: Robert A Smith; Deana Manassaram-Baptiste; Durado Brooks; Mary Doroshenk; Stacey Fedewa; Debbie Saslow; Otis W Brawley; Richard Wender Journal: CA Cancer J Clin Date: 2015-01-08 Impact factor: 508.702
Authors: Gwen Murphy; Farin Kamangar; Sanford M Dawsey; Frank Z Stanczyk; Stephanie J Weinstein; Philip R Taylor; Jarmo Virtamo; Christian C Abnet; Demetrius Albanes; Neal D Freedman Journal: J Natl Cancer Inst Date: 2011-06-21 Impact factor: 13.506